FDA approves dapagliflozin for type 2 diabetes

Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...

Field of Interest: Endocrinology
Type: News Item

‘JNC 8’ guideline follows convoluted endgame

UPDATED Jan. 4, 2014 The federally funded program to produce a set of U.S. guidelines for hypertension management, a process more than 5 years in the making, came to an unusual end on...

Field of Interest: Cardiology
Type: News Item

Genotyping adds little to optimized warfarin dosing

DALLAS – Genotyping to guide the starting dosage of warfarin treatment showed no added value above tailoring treatment with a panel of clinical features in a randomized, controlled U.S. trial of more...

Field of Interest: Cardiology
Type: News Item

Low-FODMAP diet reduced IBS symptoms

Diets low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols reduced functional gastrointestinal symptoms in patients with irritable bowel syndrome. The finding, published...

Field of Interest: Gastroentero...
Type: News Item

Golimumab maintains response in UC

Subcutaneous golimumab induces and maintains clinical response in ulcerative colitis, according to two studies in the January issue of Gastroenterology. <link...

Field of Interest: Gastroentero...
Type: News Item

Opportunities to boost cardiovascular disease awareness

DALLAS – A mere 28% of 1,013 surveyed New York–area women correctly identified cardiovascular disease as the No. 1 killer of women. And two-thirds of those women said their primary care provider is...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.